Tandem Diabetes Q3 sales rise 2% to $249.3 million; net loss narrows to $21.2 million
Tandem Diabetes Care reported third quarter 2025 results for the period ended September 30, with worldwide sales up to $249.3 million from $244.0 million a year earlier and a GAAP net loss of $21.2 million, down from $23.3 million. The company reaffirmed its full year 2025 guidance, including sales of approximately $1.0 billion, which keeps the outlook unchanged for shareholders.
Key points
- Worldwide sales were $249.3 million, including $73.6 million outside the United States, versus $244.0 million in the third quarter of 2024.
- GAAP net loss was $21.2 million, or $0.31 per share, compared with a net loss of $23.3 million, or $0.35 per share, a year earlier.
- GAAP gross margin was 54%, compared with 51% a year earlier.
- For 2025, the company reaffirmed guidance for sales of approximately $1.0 billion and an adjusted EBITDA margin of approximately negative 5% of sales.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.